Loading data for FHTX — first visit, this takes a few seconds.

Alerta

Foghorn Therapeutics Inc. (FHTX)

NasdaqGM: FHTX · Precio en tiempo real · USD

6.75

+0.01 (0.15%)

Al cierre: Aug 18, 2026, 8:00 PM

0.15% (1D)

No hay datos disponibles

Precio de compra	n/a
Capitalización de mercado	400.85M
Ingresos (TTM)	36.74M
Beneficio neto (TTM)	-64.58M
Beta	2.83
EPS (TTM)	-0.99
Ratio PER (TTM)	n/a
Adelante PE	-6.56
P/B (TTM)	-4.89
P/S (TTM)	10.91
Earnings Date	Nov 5, 2026

Precio de venta	n/a
Volumen	153,812
Volumen medio (20D)	264,100
Abierto	6.62
Anterior Cerrar	6.74
Rango del día	6.43 - 6.87
Rango de 52 semanas	3.27 - 6.95
analista	n/a
Precio objetivo	n/a
Dividendos	n/a
Fecha ex dividendo	n/a

Acerca de FHTX

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing therapies for mutant; non-small cell lung; endometrial, cervical, o...

[Leer más]

Industria Biotechnology

Sector Healthcare

IPO Fecha Oct 23, 2020

Empleados 106

Bolsa de Valores NasdaqGM

Símbolo bursátil FHTX

Sitio web https://foghorntx.com

Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Foghorn Therapeutics fueron 30.91M, un aumento de 36.75% en comparación con 22.6M del año anterior. Las ganancias fueron -74.28M, una disminución de -14.24%.

Estados financieros

Sorpresa de resultados

Foghorn Therapeutics ha publicado sus resultados trimestrales en Aug 6, 2026:

Ingresos de $16.07M falla las estimaciones por $0, con 112.68% Crecimiento interanual.

EPS de -0.1 supera las estimaciones en 0.13, con 64.29% Crecimiento interanual.

Próxima publicación de resultados

Está previsto que Foghorn Therapeutics Inc. publique sus resultados el Nov 5, 2026, antes de que se abra el mercado.
Los analistas proyectan ingresos de ... Actualizar

Noticias

4 días hace · Zacks

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Does Foghorn Therapeutics Inc. (FHTX) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 semana hace · Zacks

Wall Street Analysts Believe Foghorn Therapeutics (FHTX) Could Rally 88.47%: Here's is How to Trade

The mean of analysts' price targets for Foghorn Therapeutics (FHTX) points to an 88.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement ...

1 semana hace · Zacks

Foghorn Therapeutics Inc. (FHTX) Reports Q2 Loss, Beats Revenue Estimates

Foghorn Therapeutics (FHTX) delivered earnings and revenue surprises of +56.52% and +98.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

3 semanas hace · Zacks

Acadia Healthcare (ACHC) Surpasses Q2 Earnings and Revenue Estimates

Acadia Healthcare (ACHC) delivered earnings and revenue surprises of +15.15% and +2.50%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1 mes hace · Zacks

Foghorn Therapeutics (FHTX) Surges 5.8%: Is This an Indication of Further Gains?

Foghorn Therapeutics (FHTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price...

Página 1 de 2

Foghorn Therapeutics Inc. (FHTX)